Bristol-Myers Squibb Company (BMY)

$47.15 -0.08 (-0.17%)
Market Cap 96.13B
Revenue (ttm) 48.30B
Net Income (ttm) -8.95B
EPS (ttm) N/A
PE Ratio 7.00
Forward PE 7.23
Profit Margin -18.53%
Debt to Equity Ratio 2.81
Volume 8,513,700
Avg Vol 11,657,400
Day's Range N/A - N/A
Shares Out 2.04B
Stochastic %K 49%
Beta 0.35
Analysts Sell
Price Target $52.28

Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for oncology, hematology, immunology, cardiovascular, neuroscience, and other areas. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation and for the treatment of DVT/PE; Opdivo for various anti-cancer indications; Pomalyst/Imnovid for multiple myeloma; Orencia for...

Industry: Drug Manufacturers - General
Sector: Healthcare
Phone: 609 252 4621
Website: www.bms.com
Address:
Route 206 & Province Line Road, Princeton, United States
Micah912
Micah912 Sep. 11 at 8:00 AM
Bought $BMY November $50 calls
0 · Reply
RRCORNER
RRCORNER Sep. 11 at 12:48 AM
$SIGY Sigyn vs. Statins: Better and Faster Sigyn Therapy™ dramatically outperforms statins: - Works in a single session versus weeks or months for statins. - Lowers both LDL-C and Lp(a), unlike statins. - Reduces inflammation and immediate MACE risk. - Safe and effective for statin-intolerant patients. $PFE $BMY $DVA
0 · Reply
Gps_100X_ROI_Potential
Gps_100X_ROI_Potential Sep. 10 at 7:38 PM
$SLS was a massive Phase 3 trial, 156 locations - note all the tox detailed in the Published Data. SLS Market Cap - Net of Dilution, is UP nearly 250%, Since the IDMC Unblinded Actual Phase 3 Interim mOS and IR Trial Data. You know $ABBV and $BMY Know exactly how their Drugs Perform in this AML Second Remission Setting. - and for The SKEPTICS and SHORT Lying SBAGS, GPs is 100% For Sure Getting FDA APPROVAL - Follow the Logic: IDMC Stated No Futility at the INTERIM - Ie Gps is BETTER THAN BAT/AZA VEN--- Better OS than BAT and WITH NO TOXICITY --- Guarantees GPS APPROVAL - not even considering the SAP. SLS can Submit a BLA... Just like $GALT is doing after their P3 failed to hit endpoints... Stock Price is Up 400% on a failed P3.... Lol SLS shorts are SO FUXXED.
2 · Reply
highnihilism
highnihilism Sep. 10 at 5:16 PM
$BMY Partnering with BioNTech on an $11B cancer drug deal (BNT327), which showed 76.3% tumor shrinkage in Phase II small cell lung cancer trials. Positioned as a Keytruda challenger, which ensures an expensive arms race for oncology market share. #ETSY Etsy’s platform engagement & merchant growth are reinforcing the $72 level. Consumer-spending resilience (whimsigoth, fetish fashion, nostalgia, handmade crafts, domestic charm, heritage demand). #SG Sweetgreen’s luxury athleisure lifestyle setting: bright & clean interior, crisp greens, bright wooden textures (post-class vibe) is reinforcing the $18 level. Where energized femininity resonates. #XHB Homebuilder demand trends & housing supply dynamics are reinforcing the $120 level. Fed rate-cut speculation & “golden cross” approaching. #BTC Bitcoin’s on-chain metrics & institutional flows are propping up the $114,000 level. Fed rate-cut speculation & “liquidity expansion.”
0 · Reply
DimondTrade100
DimondTrade100 Sep. 10 at 3:01 PM
$BMY The company is in a race to commercialize its new oncology and cardiology drugs before the massive patent cliff for Eliquis and Revlimid erodes the base.
0 · Reply
Clifden
Clifden Sep. 10 at 12:04 PM
$BMY Layoffs today
0 · Reply
SuperGreenToday
SuperGreenToday Sep. 10 at 6:45 AM
$BMY The company is in a race to de-risk its pipeline and drive launches in oncology and cardiology before the massive erosion of Revlimid and Eliquis patents.
0 · Reply
DonCorleone77
DonCorleone77 Sep. 9 at 11:13 PM
$AZN $GSK $NVS $RHHBY $BMY President Trump signed a memorandum mandating that pharmaceutical advertisements increase the amount of information regarding risks of the drug in question.
0 · Reply
3DBuilds
3DBuilds Sep. 9 at 9:18 PM
$CRSP $BEAM $JNJ $BMY $UNH
0 · Reply
OptionSamurai
OptionSamurai Sep. 9 at 3:05 PM
A new candidate for a wheel strategy on our screener: $BMY 💵 Company has a fundamental score of 9 and a growth score of 9. 📈 IV percentile is 31.9% 🔮 Annualized covered call return is 39.1% You can sell a put strike 45.0 (2.0 ATRs away) for 03-Oct-25 ✅ Return is 1.7% and 25.6% annualized ✅ Breakeven is 6.0% away ✅ Dividend yield if assigned is 5.3% 🔥 See more results & create your own scan here: https://bit.ly/3lR1xIP
0 · Reply
Latest News on BMY
BioNTech, Bristol Myers Squibb Show Tumor Shrinkage In Lung Cancer Immunotherapy

Sep 8, 2025, 2:01 PM EDT - 2 days ago

BioNTech, Bristol Myers Squibb Show Tumor Shrinkage In Lung Cancer Immunotherapy

BNTX

Bristol-Myers Squibb Company (BMY) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)

Sep 8, 2025, 12:15 PM EDT - 2 days ago

Bristol-Myers Squibb Company (BMY) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)

BioNTech, Bristol Myers' immunotherapy shows encouraging tumour shrinkage in Phase II trial

Sep 8, 2025, 11:05 AM EDT - 2 days ago

BioNTech, Bristol Myers' immunotherapy shows encouraging tumour shrinkage in Phase II trial

BNTX

Bristol-Myers Squibb: Why Q2 Results Signal A Turning Point

Sep 8, 2025, 9:47 AM EDT - 2 days ago

Bristol-Myers Squibb: Why Q2 Results Signal A Turning Point

Bristol-Myers Squibb: Growth Portfolio Surpasses Legacy, Driving Oncology And Immunology Leadership

Sep 7, 2025, 9:47 AM EDT - 3 days ago

Bristol-Myers Squibb: Growth Portfolio Surpasses Legacy, Driving Oncology And Immunology Leadership

Bristol Myers Squibb: A 5% Yield And Single-Digit P/E Still Look Good

Sep 6, 2025, 7:15 AM EDT - 4 days ago

Bristol Myers Squibb: A 5% Yield And Single-Digit P/E Still Look Good

Bristol-Myers Squibb: Buy Before The Market Realizes Its Folly

Sep 5, 2025, 11:30 AM EDT - 5 days ago

Bristol-Myers Squibb: Buy Before The Market Realizes Its Folly

Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks With Over 4% Dividend Yields

Sep 4, 2025, 3:58 PM EDT - 6 days ago

Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks With Over 4% Dividend Yields

PFE XRAY

Bristol-Myers Squibb: Not As Cheap As It Might Seem

Sep 3, 2025, 5:56 PM EDT - 7 days ago

Bristol-Myers Squibb: Not As Cheap As It Might Seem

7 Big Yields From The Beat-Up Healthcare Sector

Sep 1, 2025, 10:52 AM EDT - 9 days ago

7 Big Yields From The Beat-Up Healthcare Sector

DOC LTC OHI PFE SIGA SILA

8 'Safer' Dividend Buys In Barron's 23 Better Bets (BBB) Than T-Bills August Report

Aug 31, 2025, 11:18 AM EDT - 10 days ago

8 'Safer' Dividend Buys In Barron's 23 Better Bets (BBB) Than T-Bills August Report

BBY CAG EQR KEY KIM KMI LYB

Bristol Myers Squibb Presents Real-World Outcomes of Camzyos (mavacamten) Across Four Continents at the European Society of Cardiology (ESC) Congress 2025

Aug 29, 2025, 7:35 AM EDT - 12 days ago

Bristol Myers Squibb Presents Real-World Outcomes of Camzyos (mavacamten) Across Four Continents at the European Society of Cardiology (ESC) Congress 2025

Bristol Myers Squibb to Participate in the Morgan Stanley 23rd Annual Global Healthcare Conference

Aug 29, 2025, 6:59 AM EDT - 12 days ago

Bristol Myers Squibb to Participate in the Morgan Stanley 23rd Annual Global Healthcare Conference

8 Ideal 'Safer' Dividend Dogs To Buy From 60 August Graham Value All-Stars

Aug 28, 2025, 3:51 AM EDT - 14 days ago

8 Ideal 'Safer' Dividend Dogs To Buy From 60 August Graham Value All-Stars

BBVA BNS CMCSA CNQ DHT E EOG

Bristol Myers Squibb to Present New Clinical and Real-World Data at the European Society of Cardiology Congress 2025

Aug 25, 2025, 6:59 AM EDT - 16 days ago

Bristol Myers Squibb to Present New Clinical and Real-World Data at the European Society of Cardiology Congress 2025

Final Trades: ServiceNow, Bristol Myers and Live Nation

Aug 21, 2025, 2:20 PM EDT - 20 days ago

Final Trades: ServiceNow, Bristol Myers and Live Nation

LYV NOW

Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks Delivering High-Dividend Yields

Aug 19, 2025, 1:32 PM EDT - 22 days ago

Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks Delivering High-Dividend Yields

MDT XRAY

Izalontamab Brengitecan (EGFRxHER3 ADC) Granted Breakthrough Therapy Designation by U.S. FDA for Patients with Previously Treated Advanced EGFR-Mutated Non-Small Cell Lung Cancer

Aug 18, 2025, 6:00 AM EDT - 23 days ago

Izalontamab Brengitecan (EGFRxHER3 ADC) Granted Breakthrough Therapy Designation by U.S. FDA for Patients with Previously Treated Advanced EGFR-Mutated Non-Small Cell Lung Cancer

Dogs Of The S&P 500: Buy 19 Ideal "Safer" August Dividend Payers

Aug 15, 2025, 1:34 PM EDT - 26 days ago

Dogs Of The S&P 500: Buy 19 Ideal "Safer" August Dividend Payers

AMCR ARE BXP CAG CPB CVX DOC

Dividend Harvesting Portfolio Week 232: $23,200 Allocated, $2,467.76 In Projected Dividends

Aug 14, 2025, 8:45 AM EDT - 27 days ago

Dividend Harvesting Portfolio Week 232: $23,200 Allocated, $2,467.76 In Projected Dividends

BP MO O SLB SPYI

3 SWANs On Sale

Aug 8, 2025, 7:00 AM EDT - 4 weeks ago

3 SWANs On Sale

ELV REXR

3 Dividend Stocks for August 2025

Aug 5, 2025, 11:01 AM EDT - 5 weeks ago

3 Dividend Stocks for August 2025

AMGN POR

Bristol Myers Squibb: Why I'm Pounding The Table On This Buying Opportunity

Aug 4, 2025, 10:53 PM EDT - 5 weeks ago

Bristol Myers Squibb: Why I'm Pounding The Table On This Buying Opportunity

Bristol Myers Squibb's Application for Breyanzi (lisocabtagene maraleucel) Accepted for Priority Review by U.S. Food and Drug Administration (FDA) in Fifth Cancer Type for Relapsed or Refractory Marginal Zone Lymphoma (MZL)

Aug 4, 2025, 4:16 PM EDT - 5 weeks ago

Bristol Myers Squibb's Application for Breyanzi (lisocabtagene maraleucel) Accepted for Priority Review by U.S. Food and Drug Administration (FDA) in Fifth Cancer Type for Relapsed or Refractory Marginal Zone Lymphoma (MZL)

Bristol-Myers Squibb: Buy The Weakness

Aug 4, 2025, 6:03 AM EDT - 5 weeks ago

Bristol-Myers Squibb: Buy The Weakness

Bristol-Myers Squibb: Declines Have Gone Too Far

Aug 2, 2025, 10:42 AM EDT - 5 weeks ago

Bristol-Myers Squibb: Declines Have Gone Too Far

Bristol-Myers Squibb: No Respect For Blowout Earnings - Buy The Richer Dividend Yields

Aug 1, 2025, 1:42 PM EDT - 5 weeks ago

Bristol-Myers Squibb: No Respect For Blowout Earnings - Buy The Richer Dividend Yields

Bristol-Myers Q2 Earnings Review: Solid Quarter, But Incoming CMO Must Fix Pipeline

Aug 1, 2025, 1:25 PM EDT - 5 weeks ago

Bristol-Myers Q2 Earnings Review: Solid Quarter, But Incoming CMO Must Fix Pipeline

Bristol-Myers Squibb: Growth Is Taking Its Own Time (Rating Downgrade)

Aug 1, 2025, 1:14 PM EDT - 5 weeks ago

Bristol-Myers Squibb: Growth Is Taking Its Own Time (Rating Downgrade)

Pharmaceutical makers were largely unshaken by new demands from President Trump to lower drug prices, with experts saying the measures would either have modes impact or face legal challenges

Aug 1, 2025, 12:01 PM EDT - 5 weeks ago

Pharmaceutical makers were largely unshaken by new demands from President Trump to lower drug prices, with experts saying the measures would either have modes impact or face legal challenges

ABBV AMGN AZN GILD GSK JNJ LLY

Pres. Trump's push to lower drug prices 'is a good starting point', says Dr. Scott Gottlieb

Aug 1, 2025, 8:31 AM EDT - 5 weeks ago

Pres. Trump's push to lower drug prices 'is a good starting point', says Dr. Scott Gottlieb

ABBV ABT ALNY AMGN ARGX AZN BAX

Bristol Myers: Dividend Growth, Raised Guidance, And A Double Beat

Aug 1, 2025, 8:30 AM EDT - 5 weeks ago

Bristol Myers: Dividend Growth, Raised Guidance, And A Double Beat

President Trump demands drugmakers slash prices within 60 days

Aug 1, 2025, 6:54 AM EDT - 5 weeks ago

President Trump demands drugmakers slash prices within 60 days

ABBV ABT ALNY AMGN ARGX AZN BAX

Bristol-Myers Squibb Company (BMY) Q2 2025 Earnings Call Transcript

Jul 31, 2025, 4:40 PM EDT - 5 weeks ago

Bristol-Myers Squibb Company (BMY) Q2 2025 Earnings Call Transcript

Pharma Companies Should Immediately Cut Down Drug Prices, Trump Says

Jul 31, 2025, 3:35 PM EDT - 5 weeks ago

Pharma Companies Should Immediately Cut Down Drug Prices, Trump Says

ABBV AMGN AZN GILD GSK JNJ LLY

Trump says he asked 17 drugmakers to take steps to cut U.S. prices within 60 days.

Jul 31, 2025, 3:00 PM EDT - 5 weeks ago

Trump says he asked 17 drugmakers to take steps to cut U.S. prices within 60 days.

ABBV AMGN AZN GILD GSK JNJ LLY

Trump pressures 17 pharma CEOs to cut US drug prices

Jul 31, 2025, 2:28 PM EDT - 5 weeks ago

Trump pressures 17 pharma CEOs to cut US drug prices

ABBV AMGN AZN GILD GSK JNJ LLY

Trump posts letters to 17 pharmaceutical companies about drug prices

Jul 31, 2025, 2:19 PM EDT - 5 weeks ago

Trump posts letters to 17 pharmaceutical companies about drug prices

ABBV GILD LLY PFE AMGN AZN GSK

Trump says he asked 17 drugmakers to take steps to cut U.S. prices within 60 days

Jul 31, 2025, 1:48 PM EDT - 5 weeks ago

Trump says he asked 17 drugmakers to take steps to cut U.S. prices within 60 days

ABBV AMGN AZN GILD GSK JNJ LLY

Bristol Myers posts better-than-expected second quarter results on strength of top sellers

Jul 31, 2025, 7:01 AM EDT - 5 weeks ago

Bristol Myers posts better-than-expected second quarter results on strength of top sellers

Bristol Myers Squibb Reports Second Quarter Financial Results for 2025

Jul 31, 2025, 6:59 AM EDT - 5 weeks ago

Bristol Myers Squibb Reports Second Quarter Financial Results for 2025

Buy 9 Barron's Better Bets (Than T-Bills) From 16 'Safer' July DiviDogs

Jul 30, 2025, 5:59 PM EDT - 6 weeks ago

Buy 9 Barron's Better Bets (Than T-Bills) From 16 'Safer' July DiviDogs

BBY CAG EQR FRT KIM KMI MO

How Will Bristol Myers Squibb Stock React To Its Upcoming Earnings?

Jul 30, 2025, 10:15 AM EDT - 6 weeks ago

How Will Bristol Myers Squibb Stock React To Its Upcoming Earnings?

Bristol Myers, Bain Capital form new company to develop immunology drugs

Jul 28, 2025, 5:59 PM EDT - 6 weeks ago

Bristol Myers, Bain Capital form new company to develop immunology drugs

Bristol Myers Squibb and Bain Capital Form New Immunology Company

Jul 28, 2025, 5:05 PM EDT - 6 weeks ago

Bristol Myers Squibb and Bain Capital Form New Immunology Company

Bristol Myers Squibb and Bain Capital Create New Company Dedicated to Developing Innovative Immunology Therapies that Address the Unmet Medical Needs of Patients

Jul 28, 2025, 4:16 PM EDT - 6 weeks ago

Bristol Myers Squibb and Bain Capital Create New Company Dedicated to Developing Innovative Immunology Therapies that Address the Unmet Medical Needs of Patients

Evercore ISI's Umer Raffat on finding value in the beaten-down health care sector

Jul 28, 2025, 2:06 PM EDT - 6 weeks ago

Evercore ISI's Umer Raffat on finding value in the beaten-down health care sector

ABBV CI CVS HUM MRK XBI XLV

Cristian Massacesi, M.D., Joins Bristol Myers Squibb as Executive Vice President, Chief Medical Officer and Head of Development

Jul 25, 2025, 6:59 AM EDT - 6 weeks ago

Cristian Massacesi, M.D., Joins Bristol Myers Squibb as Executive Vice President, Chief Medical Officer and Head of Development

Bristol Myers Squibb's Supplemental New Drug Application (sNDA) for Sotyktu (deucravacitinib) for the Treatment of Adults with Active Psoriatic Arthritis Accepted for Review Across Four Regions Globally

Jul 21, 2025, 6:59 AM EDT - 7 weeks ago

Bristol Myers Squibb's Supplemental New Drug Application (sNDA) for Sotyktu (deucravacitinib) for the Treatment of Adults with Active Psoriatic Arthritis Accepted for Review Across Four Regions Globally

July's 5 Dividend Growth Stocks With Yields Up To 7.96%

Jul 18, 2025, 2:46 PM EDT - 7 weeks ago

July's 5 Dividend Growth Stocks With Yields Up To 7.96%

ABBV APAM BLK EBF MRK NWE PFE

Micah912
Micah912 Sep. 11 at 8:00 AM
Bought $BMY November $50 calls
0 · Reply
RRCORNER
RRCORNER Sep. 11 at 12:48 AM
$SIGY Sigyn vs. Statins: Better and Faster Sigyn Therapy™ dramatically outperforms statins: - Works in a single session versus weeks or months for statins. - Lowers both LDL-C and Lp(a), unlike statins. - Reduces inflammation and immediate MACE risk. - Safe and effective for statin-intolerant patients. $PFE $BMY $DVA
0 · Reply
Gps_100X_ROI_Potential
Gps_100X_ROI_Potential Sep. 10 at 7:38 PM
$SLS was a massive Phase 3 trial, 156 locations - note all the tox detailed in the Published Data. SLS Market Cap - Net of Dilution, is UP nearly 250%, Since the IDMC Unblinded Actual Phase 3 Interim mOS and IR Trial Data. You know $ABBV and $BMY Know exactly how their Drugs Perform in this AML Second Remission Setting. - and for The SKEPTICS and SHORT Lying SBAGS, GPs is 100% For Sure Getting FDA APPROVAL - Follow the Logic: IDMC Stated No Futility at the INTERIM - Ie Gps is BETTER THAN BAT/AZA VEN--- Better OS than BAT and WITH NO TOXICITY --- Guarantees GPS APPROVAL - not even considering the SAP. SLS can Submit a BLA... Just like $GALT is doing after their P3 failed to hit endpoints... Stock Price is Up 400% on a failed P3.... Lol SLS shorts are SO FUXXED.
2 · Reply
highnihilism
highnihilism Sep. 10 at 5:16 PM
$BMY Partnering with BioNTech on an $11B cancer drug deal (BNT327), which showed 76.3% tumor shrinkage in Phase II small cell lung cancer trials. Positioned as a Keytruda challenger, which ensures an expensive arms race for oncology market share. #ETSY Etsy’s platform engagement & merchant growth are reinforcing the $72 level. Consumer-spending resilience (whimsigoth, fetish fashion, nostalgia, handmade crafts, domestic charm, heritage demand). #SG Sweetgreen’s luxury athleisure lifestyle setting: bright & clean interior, crisp greens, bright wooden textures (post-class vibe) is reinforcing the $18 level. Where energized femininity resonates. #XHB Homebuilder demand trends & housing supply dynamics are reinforcing the $120 level. Fed rate-cut speculation & “golden cross” approaching. #BTC Bitcoin’s on-chain metrics & institutional flows are propping up the $114,000 level. Fed rate-cut speculation & “liquidity expansion.”
0 · Reply
DimondTrade100
DimondTrade100 Sep. 10 at 3:01 PM
$BMY The company is in a race to commercialize its new oncology and cardiology drugs before the massive patent cliff for Eliquis and Revlimid erodes the base.
0 · Reply
Clifden
Clifden Sep. 10 at 12:04 PM
$BMY Layoffs today
0 · Reply
SuperGreenToday
SuperGreenToday Sep. 10 at 6:45 AM
$BMY The company is in a race to de-risk its pipeline and drive launches in oncology and cardiology before the massive erosion of Revlimid and Eliquis patents.
0 · Reply
DonCorleone77
DonCorleone77 Sep. 9 at 11:13 PM
$AZN $GSK $NVS $RHHBY $BMY President Trump signed a memorandum mandating that pharmaceutical advertisements increase the amount of information regarding risks of the drug in question.
0 · Reply
3DBuilds
3DBuilds Sep. 9 at 9:18 PM
$CRSP $BEAM $JNJ $BMY $UNH
0 · Reply
OptionSamurai
OptionSamurai Sep. 9 at 3:05 PM
A new candidate for a wheel strategy on our screener: $BMY 💵 Company has a fundamental score of 9 and a growth score of 9. 📈 IV percentile is 31.9% 🔮 Annualized covered call return is 39.1% You can sell a put strike 45.0 (2.0 ATRs away) for 03-Oct-25 ✅ Return is 1.7% and 25.6% annualized ✅ Breakeven is 6.0% away ✅ Dividend yield if assigned is 5.3% 🔥 See more results & create your own scan here: https://bit.ly/3lR1xIP
0 · Reply
SniperPro
SniperPro Sep. 9 at 2:32 PM
✨ $BMY $NVO $JNJ $MRK $LXRX ✨ One of the big pharmaceutical companies is strongly backing Little Lex... I wonder who it is? FDA better play fair... 👉 *NOVO are you the ONE? Take us to higher grounds... * Besides the $1B dollar deal already agreed...
0 · Reply
wwmeinc
wwmeinc Sep. 8 at 3:57 PM
$IOVA .... $BMY and $BNTX moving along in their $~$11B JV....Ahhh....if only BMY looked at our(IOVA)product to JV...but so far, not to be(never say never though)...and others are always welcomed to JV though ;)....yes...I know...not an apples to apples drug therapy/treatment comparison for Amtagvi but the goal is treatments.....saving patients with whatever product/treatment/therapy that patients can avail themselves to...I am always an optimist for advancing medical science but mgmt can wreck wonders if given enough rope....just some thoughts...glta "The drug is already being tested in a Phase III lung cancer trial. Bristol Myers in June agreed to pay up to $11.1 billion to collaborate with BioNTech on the experimental drug, betting on a next-generation cancer immunotherapy that could take on rival Merck & Co's best-selling drug Keytruda." https://www.reuters.com/business/healthcare-pharmaceuticals/biontech-bristol-myers-immunotherapy-shows-encouraging-tumour-shrinkage-phase-ii-2025-09-08/
1 · Reply
complexoptions
complexoptions Sep. 8 at 2:11 PM
$BMY thisbis value trap
0 · Reply
Walnuts86
Walnuts86 Sep. 8 at 1:35 PM
$BMY what’s up here?
0 · Reply
Quantumup
Quantumup Sep. 8 at 10:25 AM
Citizens⬆️ $IDYA's PT to $45 from $41, reiterated at a Market Outperform and said, IDEAYA Biosciences's partner Hengrui showed strong numbers with DLL3-ADC IDE849 (SHR4849) in updated Ph1 data in Chinese patients that cleared the hurdle with more room than anticipated. $AZN $RHHBY $BMY $ZLAB ABBV Citizens added, IDE849 checked all the boxes and showed best-in-class efficacy as well as duration compared to the competitive landscape (details inside). We point to $IDYA's R&D day on Monday morning for more details and we expect the stock to react positively (+10%) on this strong update. We maintain our Market Outperform rating and increase our DCF-derived price target to $45 from $41 based on an increased probability of success (25% from 15%) for IDE849.
0 · Reply
framus_morrigan
framus_morrigan Sep. 7 at 4:38 PM
$BMY Doji candle and 50%-61.80% fibo retracement held this week. Potential iHS pattern is still in play until proven otherwise. Weekly chart
2 · Reply
Dogtag
Dogtag Sep. 7 at 12:54 PM
$SLS I think the only thing that can go wrong is the dealership won’t have the right color of Porsche when we see the Phase 3 results. 🤔 $GILD with a failed drug $ABBV + $BMY with a failed combo. Yet both sellas life science drugs have been successful every step of the way
1 · Reply
YouOnlyLiveTwice
YouOnlyLiveTwice Sep. 5 at 6:58 PM
$BMY VALUE TRAP W rate cuts coming investors will be chasing growth NOT dividends .. This company has NO growth
2 · Reply
Walnuts86
Walnuts86 Sep. 5 at 4:49 PM
$BMY one of the very best values out there. Dividend and very low P/E (7x vs historical 15x) $MSOS rescheduling upcoming. Just don’t know why trump Wouldn’t….40/50 states legalized in some form with 24 recreational $TGT too cheap imo. Dividend with 120 by end of year $BABA 200 + in a year
1 · Reply
Sellasgps24BAT9
Sellasgps24BAT9 Sep. 5 at 12:16 PM
$ABBV $BMY $SLS GPS is actually treating the worst stage MDS Patients as the disease progresses into AML and when it gets there it becomes fatal a lot faster. So this can really be huge, back the brinks truck up type stuff taking place here at Sellas. 🤨✌️
1 · Reply
Quantumup
Quantumup Sep. 5 at 10:58 AM
Truist🏁 $RVMD Buy/$99. $BBOT $DAWN $ERAS $BMY Truist said in its initiation report: Revolution Medicines (RevMed, $RVMD) has gone big in targeting one of the biggest drivers of cancer (RAS) where mutations drive one-third of all new cancer diagnoses. The company has built the broadest pipeline attacking these targets - most of them first-in-class - including a coveted multi-target "pan" inhibitor (Daraxonrasib), which we project to be a $8B+ drug, and will accelerate faster than implied by consensus. We think the current share price is missing the revolutionary potential of $RVMD's drugs when used in combinations, but we believe these features will gain appreciation in the next 12-18 months as new data emerges. We rate $RVMD a Buy, with a $99 PT.
0 · Reply
framus_morrigan
framus_morrigan Sep. 5 at 8:31 AM
$BMY I'm still betting on a right shoulder in development ...
1 · Reply